LiDCO technologies highlighted in NHS report on the adoption of Intraoperative Fluid Management
LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce that its technologies are highlighted in the latest NHS report, published on 8-May, on the adoption of Intraoperative Fluid Management Technologies (IOFMT). Following a commission by the Department of Health, the NHS Technology Adoption Centre published Intraoperative Fluid Management Technologies Adoption Pack, which aims to guide the successful implementation of IOFMT across the NHS in England.
The report, which highlights LiDCO's fluid management technology among others, informs all NHS organisations of the steps they need to take in order to start using or increase their use of these technologies
The report reiterates that full adoption across the NHS is forecast by NICE to benefit 837,000 patients and generate net financial savings of £400m per annum. In recognition of the improved patient outcomes, adoption of fluid optimization technologies has been included as a pre-qualifier for CQUIN (commissioning for quality and innovation) payments from 2013/14.
Of the 800,000 patients a year in the UK who are applicable for such advanced monitoring, less than 10% are currently monitored. This illustrates the potential size of the UK market and the very substantial opportunity available to LiDCO.
Dr Terry O'Brien, CEO LiDCO Group Plc, stated: "This is another major milestone in realizing the NHS's vision of implementing fluid optimisation for 800,000 applicable patients and the substantial positive outcomes both clinically and economically that will ensue. This is a terrific endorsement for the area, and we greatly welcome the opportunity this presents for LiDCO's fluid monitoring technology, which is already in wide use across the NHS."
LiDCO is a supplier of minimally invasive hemodynamic monitoring equipment and disposables to hospitals. These products are used primarily for the management of adult hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology can significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.
The Company's sales office is in Cambridge, its manufacturing facility / general administration base is in Hoxton, London, and its current products are:
* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)
* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management. The monitor enables acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being both during and after surgery. These benefits are:
Early and rapid warning of change
Clear indication of therapeutic route: fluid or drug
Quantification of hemodynamic response, particularly stroke volume
Permits more effective delivery of fluids - the right amount at the right time
Advanced hemodynamic care has been shown to contribute to:
- Reduced morbidity and complications, length of stay& overall cost of care
* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid.
* LiDCOview:an easy-to-use graphical display of historical LiDCOplusandLiDCOrapidhemodynamic data.
* LiDCO's Distribution Network:
The Company sells via its own direct sales force to hospitals in the UK, and in export markets predominantly through a worldwide network of speciality critical care and anesthesia distributors.
This information is provided by RNS
The company news service from the London Stock Exchange
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.